中文 / English
Company Profile
Company profile
BIONNA
BIONNA (Beijing) Medicine Co., Ltd. is a research and development (R&D)-driven enterprise that applies the concept of "Quality by Design (QbD)" to all aspects of drug R&D, and has created a pharmaceutical C&MC development platform, a pharmaceutical crystallization/powder engineering platform, and a suspension process development platform; based on the enterprise's technical platform, it has completed the development of multiple drug substances for inhalation preparations and complex preparations, and determined the crystallization process or powder properties of different products. From the preparation of gram-grade compounds to the commercial production of active substances, we can undertake CRO/CDMO/CMO business at different stages. At present, the self-developed products have covered respiratory, antiviral, antitumor and other fields.
Development History
history
2016
In 2016, BIONNA (Beijing) Medicine was established and a R&D team was created
2017
In 2017, the C&MC platform was built, the API R&D of inhalation preparation was carried out, and the CRO business was arranged
2018
In 2018, China’s first-class pharmaceutical powder engineering platform was built
2019
In 2019, the process development, quality study and pilot scale-up of API of multiple inhalation preparations were completed; meanwhile, we established cooperation with domestic and foreign inhalation preparation enterprises
2020
In 2020, pre-A round of financing was completed, with BIONNA Medicine (688166. SH) as the lead investor, and Breathgreen (Shandong) Pharmaceutical Co., Ltd. was established
2021
In 2021, the construction and trial operation of the cGMP plant covering an area of 40 mu was completed; and the company was awarded the National High Tech Enterprise, Deloitte-Yizhuang High-tech High-growth Top 20
2022
In 2022, the drug substance products of inhalation preparations were transferred and registered for production in the cGMP plant, and the drug production license was obtained; CDMO business was started; the founder was awarded “Yiqilin” talents of Beijing Economic and Technological Development Zone
2016
2017
2018
2019
2020
2021
2022
Corporate Culture
corporate culture
Core Mission
使命
Alleviate Patient Pain
Core Values
价值
Responsibility/Integrity/Fairness
Corporate Culture
文化
Direct/Transparent/Innovative/Collaborative
Enterprise Features
特色
Frontier/Compliance/Internationalization
Company Honors
honors
Founding Team
team
Kun Yin/ President
Worked at General Electric (GE) in the United States and Weidmuller in Germany
Bachelor Degree in Industrial Automation, North China Electric Power University
EMBA, Guanghua School of Management, Peking University
Hao Li, Ph.D./ General Manager
Former Pharmaceutical Chemistry Scientist, Forma Therapeutics, Singapore
Former Senior Scientist, Pharmaceutical Chemistry, AMRI, Singapore
 Former Senior Process Research Scientist, GlaxoSmithKline, Singapore
 PhD, Nanyang Technological University, Singapore
Kiewching Lee, Ph.D./ Chief Scientist Officer
Former Chief Scientist Officer, GlaxoSmithKline Centre for Central Nervous Drug Development
Former GlaxoSmithKline Directing Professor of Industry: University of Edinburgh, UK (MSc), Monash University, Australia (PhD), University of Montpellier 1, France (MSc)
PhD, National University of Singapore
Baoli Cai/ Vice General Manager
Director of Generic Drug Development & Director of Drug Substance Technology Transfer
Bachelor of Pharmaceutical Engineering, Hebei University of Technology/Master of Organic Chemistry, Nankai University
Over 12 years of factory scale-up experience with more than 50 projects
Dr Loh Teck Peng/ 资深顾问
◆ 南京工业大学化学与分子工程学院院长,先进化学制造研究院院长
◆ 中组部千人计划专家
◆ 美国哈佛大学博士,师从诺贝尔奖得主E. J. Corey 教授
◆ 新加坡国立大学教授
◆ 新加坡南洋理工大学化学与生物化学系系主任,数理学院副院长
吴明娟/ 财务总监

◆ 上海立信会计金融学院 会计师

◆ 前中石化茂华财务经理

◆ 18年特大型上市企业财务相关工作经验

刘微/ 行政经理
汪义丰 教授/ 化学顾问

◆ 中国科技大学化学与化工学院教授
◆ 2014 中组部青年千人计划专家
◆ 新加坡南洋理工大学博士


王超/ 销售经理
Dr Wong Shin Yee/ 结晶工艺顾问
◆ 新加坡科技学院副教授
◆ 前葛兰素(新加坡)高级研究员-GMP 生产/工艺转移
◆ 麻省理工博士后-连续反应工艺
◆ 威斯康辛麦迪逊分校博士-结晶工艺
赵玉军 教授/ 药化顾问
◆ 中国科学院上海药物所研究员
◆ 2014 中组部青年千人计划专家
◆ 新加坡南洋理工大学博士
◆ 美国密执安大学博士后
◆ 博后期间从事多项肿瘤新药研发,并成功以3.98亿美元转让给赛诺菲
◆ 在J. Am. Chem. Soc., J. Med. Chem., Chem.Comm.; Org.Lett 等国际著名期刊发表论文10篇,PCT专利3篇
毕秀丽 教授/ 药理顾问
◆ 辽宁大学生科院教授
◆ 沈阳药科大学药理学博士
◆ 美国阿拉巴马州立大学博士后
◆ 美国伊利诺斯大学芝加哥分校博士后 讲师
Cooperative Partner
cooperative partner